Industry veteran takes key leadership role to expand reach of innovative robotics company
WALTHAM, MA - October 8, 2015 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that it named Gary Lickovitch as Vice President of Sales and Service effective October 5, 2015. Mr. Lickovitch will report directly to Corindus' President and CEO, David Handler.
"I am thrilled to have Gary join Corindus in this important commercial leadership position. He has a tremendous track record in bringing new technology and innovation to interventional cardiology customers," said Handler. "Gary's deep clinical understanding of interventional procedures and cath lab devices, in conjunction with his strong sales leadership skills and customer relationships, are tremendous assets which have enabled him to consistently deliver impressive sales growth results throughout his career."
Mr. Lickovitch brings nearly 20 years of medical device sales leadership experience to his role at Corindus. He most recently served at Boston Scientific (NYSE: BSX) as Area Vice President for the Interventional Cardiology Division responsible for sales execution and strategy. He also held prior sales leadership roles at vascular medical device companies Abbott Vascular (NSYE: ABT) and CR Bard (NYSE: BCR).
"I'm extremely excited to join Corindus. Knowing the cath lab, and the occupational hazards facing its physicians and staff, it is very important to protect these workers from radiation and orthopedic injuries by bringing precision capabilities to interventional procedures," said Lickovitch. "I believe that the CorPath® System's robotic-assistance technology will become the standard for PCI in the coming years."
For more information about the CorPath System, visit www.corindus.com or schedule a demo during the upcoming TCT 2015 Meeting at the Corindus Vascular Robotics Booth #1525.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements:
